Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 2/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.43 |
| ▸ | GRM5 | P41594 | 7/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24718042 | 0.88 | PDK4 (0.48) | PDK4WDR5JAK1GRM1GRM5 | |
| SCHEMBL30798488 | 0.88 | PDK4 (0.48) | PDK4WDR5JAK1GRM1GRM5 | |
| SCHEMBL3226352 | 0.88 | MAPT (0.37) | WDR5 | |
| SCHEMBL1763861 | 0.85 | PDK4 (0.50) | PDK4WDR5SOS1JAK1GRM1 | |
| SCHEMBL1764110 | 0.84 | PDK4 (0.49) | PDK4JAK1GRM1GRM5SCN9A | |
| SCHEMBL1763983 | 0.82 | PDK4 (0.47) | PDK4WDR5SOS1JAK1GRM1 | |
| SCHEMBL30736760 | 0.81 | NAMPT (0.52) | PDK4WDR5SOS1JAK1GRM1 | |
| SCHEMBL30736692 | 0.81 | NAMPT (0.52) | PDK4WDR5SOS1JAK1GRM1 | |
| SCHEMBL3033965 | 0.79 | NAMPT (0.54) | PDK4SOS1JAK1GRM1GRM5 | |
| SCHEMBL31700764 | 0.79 | PDK4 (0.53) | PDK4JAK1GRM1GRM5SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | PDK4 717/4885WDR5 4243/4885SOS1 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.